Novartis Hopes For Canakinumab In Lung Cancer Nosedive
Second Phase III Fail In NSCLC
After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.
